IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+3.95%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$672M
AUM Growth
+$672M
(+23%)
Cap. Flow
+$83.3M
Cap. Flow
% of AUM
12.4%
Top 10 Holdings %
Top 10 Hldgs %
24.63%
Holding
266
New
64
Increased
37
Reduced
43
Closed
20
Top Buys
| 1 |
Eli Lilly
LLY
|
$23.4M |
| 2 |
MacroGenics
MGNX
|
$15.9M |
| 3 |
Galapagos
GLPG
|
$15.5M |
| 4 |
X4 Pharmaceuticals
XFOR
|
$15.4M |
| 5 |
Relmada Therapeutics
RLMD
|
$10.2M |
Top Sells
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$29.5M |
| 2 |
KalVista Pharmaceuticals
KALV
|
$19.7M |
| 3 |
Prothena Corp
PRTA
|
$18.8M |
| 4 |
Bristol-Myers Squibb
BMY
|
$17.9M |
| 5 |
Celldex Therapeutics
CLDX
|
$15.8M |
Sector Composition
| 1 | Healthcare | 98.54% |
| 2 | Consumer Staples | 0.23% |
| 3 | Financials | 0.12% |
| 4 | Industrials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Quantum-Si Incorporated
QSI
$217M
| $3.1M | 0.1% |
+260,000
| New | +$3.1M |
|
77
Sutro Biopharma
STRO
$85.6M
| $3.08M | 0.1% |
135,360
-480,000
| -78% | -$10.9M |
|
78
CASI Pharmaceuticals
CASI
$36.1M
| $3.04M | 0.1% |
1,268,154
| – | – |
|
|
TCRR
79
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $3.01M | 0.1% |
136,486
+15,000
| +12% | +$331K |
|
80
Cytokinetics
CYTK
$5.98B
| $2.95M | 0.1% |
127,000
-100,000
| -44% | -$2.33M |
|
81
Gyre Therapeutics
GYRE
$734M
| $2.93M | 0.1% |
+581,200
| New | +$2.93M |
|
82
Immatics
IMTX
$662M
| $2.86M | 0.1% |
255,138
-382,956
| -60% | -$4.29M |
|
83
INmune Bio
INMB
$52.4M
| $2.78M | 0.09% |
233,576
+16,008
| +7% | +$190K |
|
84
Madrigal Pharmaceuticals
MDGL
$9.7B
| $2.77M | 0.09% |
23,654
| – | – |
|
85
InflaRx
IFRX
$117M
| $2.73M | 0.09% |
699,750
+550,000
| +367% | +$2.14M |
|
86
Avalo Therapeutics
AVTX
$139M
| $2.71M | 0.09% |
897,330
+694,465
| +342% | +$2.1M |
|
87
Eledon Pharmaceuticals
ELDN
$155M
| $2.68M | 0.09% |
+250,000
| New | +$2.68M |
|
88
Nuvation Bio
NUVB
$1.08B
| $2.61M | 0.09% |
250,000
+48,192
| +24% | +$504K |
|
89
Altimmune
ALT
$325M
| $2.57M | 0.09% |
181,941
+106,496
| +141% | +$1.5M |
|
90
Liquidia Corp
LQDA
$2.52B
| $2.56M | 0.09% |
951,400
| – | – |
|
91
Passage Bio
PASG
$22.7M
| $2.55M | 0.09% |
145,858
+9,161
| +7% | +$160K |
|
92
Astria Therapeutics
ATXS
$394M
| $2.46M | 0.08% |
852,998
+202,998
| +31% | +$586K |
|
|
ZGNX
93
DELISTED
Zogenix, Inc.
ZGNX
| $2.42M | 0.08% |
124,091
-50,000
| -29% | -$976K |
|
|
FNCH
94
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
| $2.39M | 0.08% |
+150,000
| New | +$2.39M |
|
95
Merus
MRUS
$5.04B
| $2.32M | 0.08% |
111,223
-425,698
| -79% | -$8.89M |
|
96
Zai Lab
ZLAB
$3.48B
| $2.25M | 0.08% |
+17,000
| New | +$2.25M |
|
97
Orchestra BioMed
OBIO
$147M
| $2.25M | 0.08% |
+200,000
| New | +$2.25M |
|
98
Cyclacel Pharmaceuticals
CYCC
$17.2M
| $2.13M | 0.07% |
300,000
-91,450
| -23% | -$668K |
|
|
AGTC
99
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $2.11M | 0.07% |
415,884
-130,000
| -24% | -$659K |
|
|
RGLS
100
DELISTED
Regulus Therapeutics
RGLS
| $1.94M | 0.07% |
+1,245,989
| New | +$1.94M |
|